<p>A city-based biotechnology startup Pandorum Technologies today said it has developed artificial 3D bio-printed liver tissues.<br /><br /></p>.<p>Pandorum's artificial liver tissues not only represent a major step towards the on-demand manufacturing of human organs for transplant, but also has potential to be a game changer for developing new medicines and vaccines, the company said in a statement.<br /><br />"Liver toxicity and drug metabolism are the key hurdles, and contributors to failed human trials. Our 3D bio-printed mini-livers that mimic the human liver will serve as test platforms for discovery and development of drugs with better efficacy, less side-effects and at lower costs," Pandorum Technologies MD and co-founder Arun Chandru said.<br /><br />The 3D printed living tissues enables affordable medical research with reduced animal and human trials, and eventually leads to full scale transplantable organs, the Pandorum Technologies said.<br /><br />"This is a significant milestone," Dr Tuhin Bhowmick, who holds a PhD from Indian Institute of Science and Pandorum Technologies co-founder said.<br /><br />"Being able to engineer complex tissues such as the human liver is no easy task," he added.<br /><br />"Development of artificial organs has numerous clinical uses. Cell based organoids can be used to develop bio-artificial liver support systems for preserving life in patients who have developed liver failure.<br /><br />"In the near future, such bio-printed organs will address the acute shortage of human organs available for surgical transplantation," Bhowmick said.<br /><br />Pharma giants on an average spend upward of US $10 Billion and 10 years on R&D to get a single new drug to market with the approval of the Food and Drug Administration (FDA). The global market for in vitro toxicity testing alone is expected to reach USD 4 billion by 2018.<br /><br />"It is a multi-billion dollar fast growing market, and we intend to continue being a leader. More importantly, our technology has the potential to impact millions of lives," Chandru said.<br /><br />Pandorum Technologies, founded in 2011 by an academic entrepreneurs, is a biotechnology startup with distinct synergy of life science and engineering competencies.<br />The company works on design and manufacturing of functional human tissues for medical research, therapeutic and other applications.<br /><br />Pandorum is supported by grants from the Biotechnology Industry Research Assistance Council (BIRAC), Government of India, and is located in the Centre for Cellular and Molecular Platforms (C-CAMP), Bengaluru Bio-Cluster. <br /></p>
<p>A city-based biotechnology startup Pandorum Technologies today said it has developed artificial 3D bio-printed liver tissues.<br /><br /></p>.<p>Pandorum's artificial liver tissues not only represent a major step towards the on-demand manufacturing of human organs for transplant, but also has potential to be a game changer for developing new medicines and vaccines, the company said in a statement.<br /><br />"Liver toxicity and drug metabolism are the key hurdles, and contributors to failed human trials. Our 3D bio-printed mini-livers that mimic the human liver will serve as test platforms for discovery and development of drugs with better efficacy, less side-effects and at lower costs," Pandorum Technologies MD and co-founder Arun Chandru said.<br /><br />The 3D printed living tissues enables affordable medical research with reduced animal and human trials, and eventually leads to full scale transplantable organs, the Pandorum Technologies said.<br /><br />"This is a significant milestone," Dr Tuhin Bhowmick, who holds a PhD from Indian Institute of Science and Pandorum Technologies co-founder said.<br /><br />"Being able to engineer complex tissues such as the human liver is no easy task," he added.<br /><br />"Development of artificial organs has numerous clinical uses. Cell based organoids can be used to develop bio-artificial liver support systems for preserving life in patients who have developed liver failure.<br /><br />"In the near future, such bio-printed organs will address the acute shortage of human organs available for surgical transplantation," Bhowmick said.<br /><br />Pharma giants on an average spend upward of US $10 Billion and 10 years on R&D to get a single new drug to market with the approval of the Food and Drug Administration (FDA). The global market for in vitro toxicity testing alone is expected to reach USD 4 billion by 2018.<br /><br />"It is a multi-billion dollar fast growing market, and we intend to continue being a leader. More importantly, our technology has the potential to impact millions of lives," Chandru said.<br /><br />Pandorum Technologies, founded in 2011 by an academic entrepreneurs, is a biotechnology startup with distinct synergy of life science and engineering competencies.<br />The company works on design and manufacturing of functional human tissues for medical research, therapeutic and other applications.<br /><br />Pandorum is supported by grants from the Biotechnology Industry Research Assistance Council (BIRAC), Government of India, and is located in the Centre for Cellular and Molecular Platforms (C-CAMP), Bengaluru Bio-Cluster. <br /></p>